Casi pharmaceuticals announces third quarter 2023 business and financial updates

Beijing , nov. 14, 2023 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended september 30, 2023.  dr. wei-wu he, chairman and ceo of casi pharmaceuticals, stated, "we are delighted to announce that our partner juventas has received approval from the china national medical products administration (nmpa) for inaticabtagene autoleucel (anti-cd 19 car-t cell therapy) for the treatment of b-cell acute lymphoblastic leukemia (r/r b-all) in china.
CASI Ratings Summary
CASI Quant Ranking